Michael Byrne, DO
Hematology · Nashville, TNNPI 1316112634
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,320 of the $17,679 with a category attached, or 75.3%. 21 manufacturers reported payments, led by Gilead at 39.2% of the total. Reporting peaked in 2022 at $9,050 and has fallen 93.1% since, to $625 in 2025.
Across 52 payments — averaging $339.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Novartis$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Kadmon Pharmaceuticals LLC$1K
- CTI Biopharma Corp.$1K
- AbbVie$611
- plus $1K from 15 others
Across 122 payments — averaging $18,451 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Macrogenics, Inc.$326K
- Gilead$149K
- Beone Medicines Ltd.$138K
- Karyopharm Therapeutics Inc.$112K
- Astellas Pharma Global Development$103K
- plus $275K from 9 others
What the payments were for
- Consulting fees$13,32075%
- Speaking & faculty fees$1,2507%
- Travel & lodging$1,4178%
- Food & beverage$1,69310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 10 | $6,931 |
| Novartis | 13 | $3,562 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,865 |
| Kadmon Pharmaceuticals LLC | 1 | $1,380 |
| CTI Biopharma Corp. | 2 | $1,328 |
| AbbVie | 4 | $611 |
| Jazz Pharmaceuticals Inc. | 2 | $258 |
| Karyopharm Therapeutics Inc. | 2 | $163 |
| Stemline Therapeutics Inc. | 1 | $119 |
| Bristol Myers Squibb | 2 | $90 |
| AstraZeneca | 1 | $70 |
| Pfizer | 3 | $58 |
| Epizyme, Inc. | 1 | $46 |
| Astellas Pharma US Inc | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| GSK | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,679 in reported general payments places this provider in the 65th percentile of 23 hematology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 18 | $326,619 |
| RevlimidLenalidomide | 27 | $320,596 |
| XospataGilteritinib Fumarate | 12 | $317,364 |
| PromactaEltrombopag Olamine | 11 | $247,551 |
| ImbruvicaIbrutinib | 12 | $181,104 |
| VenclextaVenetoclax | 49 | $163,328 |
| Voriconazole | 27 | $6,551 |
| Cyclosporine | 13 | $5,680 |
| ValacyclovirValacyclovir Hcl | 149 | $3,301 |
| Fluconazole | 24 | $1,067 |
| Oxycodone Hcl | 40 | $841 |
| Dexamethasone | 43 | $524 |
| Levofloxacin | 38 | $364 |
| Ondansetron OdtOndansetron | 22 | $328 |
| Prednisone | 46 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta | $3,562 | $574,17029 claims |
| Bristol Myers SquibbRevlimid | $90 | $320,59627 claims |
| Astellas Pharma US IncXospata | $39 | $317,36412 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $181,10412 claims |
| AbbVieVenclexta | $611 | $163,32849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 23 hematology providers in Tennessee.
Other hematology in Nashville
- Stephen StricklandNashville$120K
- Michael SavonaNashville$100K
- Ashwin KishtagariNashville$88K
- Navneet MajhailNashville$58K
- Adetola KassimNashville$26K
- Robert CornellNashville$17K
- Anne NeffNashville$5K
- Silvia BuntingNashville$4K
- Wesam AhmedNashville$4K
- Phyu Thin NaingNashville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.